Interleukin-2—activated lymphocytes from brain tumor patients. A comparison of two preparations generatedin vitro
Carol A. Kruse(University of California, Los Angeles), Gary W. Mierau(Children's Hospital Colorado), Kevin O. Lillehei(University of Colorado Health), Stephen D. Johnson(St. Joseph Hospital), George E. Moore(University of Colorado Denver), Sharon Waldrop(University of Colorado Health), Dawn H. Mitchell(University of Colorado Health), E. Larry McCleary(Children's Hospital Colorado)
Cited by 27
Related Papers
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
|Journal of Translational Medicine|2018|540
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
|JAMA Oncology|2022|411
Rhabdoid Tumor of Kidney
|The American Journal of Surgical Pathology|1989|404
Three Linked Vasculopathic Processes Characterize Kawasaki Disease: A Light and Transmission Electron Microscopic Study
|PLoS ONE|2012|394
Histiocytosis X
|Human Pathology|1983|172